RhumbLine Advisers
GNMX

RhumbLine Advisers’s Aevi Genomic Medicine Inc GNMX Stock Holding History

RhumbLine Advisers’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-28,185
Closed -$52K – 2984
2017
Q1 		$52K Buy
28,185
+1,274
+5% +$5.76K ﹤0.01% 2821
2016
Q4 		$139K Buy
26,911
+2,093
+8% +$11K ﹤0.01% 2756
2016
Q3 		$138K Sell
24,818
-8,900
-26% -$50.7K ﹤0.01% 2761
2016
Q2 		$187K Buy
33,718
+15,333
+83% +$80.5K ﹤0.01% 2774
2016
Q1 		$81K Buy
18,385
+200
+1% +$823 ﹤0.01% 2926
2015
Q4 		$109K Buy
18,185
+4,130
+29% +$28K ﹤0.01% 2939
2015
Q3 		$110K Buy
14,055
+575
+4% +$4.46K ﹤0.01% 2932
2015
Q2 		$83K Buy
+13,480
New +$104K ﹤0.01% 3015

Other funds holding GNMX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

RhumbLine Advisers's GNMX Position: Q2 2017 in Review

RhumbLine Advisers sold out of Aevi Genomic Medicine Inc (GNMX) in Q2 2017, closing a stake of 28,185 shares — an estimated $52K sold.

RhumbLine Advisers first reported a position in GNMX in Q2 2015 and held it in 8 quarters. The position peaked at $187K in Q2 2016. 51 funds tracked by Wall St. Rank hold GNMX as of Q2 2017.

  • RhumbLine Advisers reported no remaining Aevi Genomic Medicine Inc position as of Q2 2017 after selling out during the quarter.
  • RhumbLine Advisers sold 28,185 Aevi Genomic Medicine Inc shares in Q2 2017, an estimated $52K.
  • RhumbLine Advisers first reported a position in Aevi Genomic Medicine Inc in Q2 2015 and held it in 8 quarters.
  • RhumbLine Advisers's Aevi Genomic Medicine Inc position peaked at $187K in Q2 2016.
  • 51 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q2 2017.

Based on RhumbLine Advisers's 13F filing for Q2 2017, filed 2 Aug 2017.